-
公开(公告)号：US09006399B2
公开(公告)日：2015-04-14
申请号：US13818645
申请日：2011-08-23
申请人： Yong-Jun Liu , Kui Shin Voo , Laura Bover , Naoya Tsurushita , J. Yun Tso , Shankar Kumar
发明人： Yong-Jun Liu , Kui Shin Voo , Laura Bover , Naoya Tsurushita , J. Yun Tso , Shankar Kumar
IPC分类号： C07K16/28 , A61K39/395 , A61K39/00
CPC分类号： C07K16/2878 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/74 , C07K2317/75
摘要： Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.
摘要翻译： 公开了与人OX40特异性结合的人抗体，优选重组人抗体，人源化和嵌合。 优选的抗体对OX40受体具有高亲和力，并在体外和体内激活受体。 抗体可以是全长抗体或其抗原结合部分。 抗体或抗体部分可用于调节受体活性，例如在患有OX40活性有害的病症的人类受试者中。 提供用于表达重组人抗体的核酸，载体和宿主细胞，并提供合成重组人抗体的方法。
-
公开(公告)号：US20130280275A1
公开(公告)日：2013-10-24
申请号：US13818645
申请日：2011-08-23
申请人： Yong-Jun Liu , Kui Shin Voo , Laura Bover , Naoya Tsurushita , J. Yun Tso , Shankar Kumar
发明人： Yong-Jun Liu , Kui Shin Voo , Laura Bover , Naoya Tsurushita , J. Yun Tso , Shankar Kumar
IPC分类号： C07K16/28
CPC分类号： C07K16/2878 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/74 , C07K2317/75
摘要： Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.
-
公开(公告)号：US20110250213A1
公开(公告)日：2011-10-13
申请号：US13082352
申请日：2011-04-07
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2317/73 , C07K2317/76
摘要： The invention provides monoclonal antibodies that specifically bind to CD122, which is one component of receptors for IL-2 and IL-15. The monoclonal antibodies have the capacity for substantial inhibition of both IL-2 and IL-15 mediated functions by inhibiting binding of these cytokines to their receptors. The monoclonal antibodies can be used for inhibiting undesired immune responses or treatment of cancer, among other applications.
摘要翻译： 本发明提供了特异性结合CD122的单克隆抗体，CD122是IL-2和IL-15受体的一个组分。 通过抑制这些细胞因子与其受体的结合，单克隆抗体具有对IL-2和IL-15介导的功能的显着抑制的能力。 除了其它应用之外，单克隆抗体可用于抑制不期望的免疫应答或癌症的治疗。
-
4.发明申请HUMANIZED ANTIBODIES SPECIFIC FOR AMINO ACID SEQUENCE RGD OF AN EXTRACELLULAR MATRIX PROTEIN AND THE USES THEREOF 有权非特异性基质蛋白氨基酸序列特异性的人类抗体及其用途公开(公告)号：US20110091386A1
公开(公告)日：2011-04-21
申请号：US12989208
申请日：2009-04-24
申请人： Shankar Kumar , J. Yun Tso , Naoya Tsurushita , Shigeyuki Kon , Toshimitsu Uede
发明人： Shankar Kumar , J. Yun Tso , Naoya Tsurushita , Shigeyuki Kon , Toshimitsu Uede
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/30 , C07K2317/24
摘要： The present invention provides humanized antibodies that immunospecifically recognize the RGD sequence. Some of these antibodies inhibit the biological functions of the RGD proteins, thereby exhibiting therapeutic effects on various disorders or diseases that are associated with RGD proteins, including cancer, e.g., the growth and metastasis of a cancer cell, and inflammatory diseases, e.g., rheumatoid arthritis, osteoarthritis, hepatitis, endometriosis, bronchial asthma, fibrosis, diabetes, arteriosclerosis, multiple sclerosis, granuloma, an inflammatory bowel disease (ulcerative colitis and Crohn's disease), an autoimmune disease, and so forth.
摘要翻译： 本发明提供免疫特异性识别RGD序列的人源化抗体。 这些抗体中的一些抑制RGD蛋白的生物学功能，从而对与RGD蛋白相关的各种疾病或疾病表现出治疗效果，包括癌症，例如癌细胞的生长和转移，以及炎性疾病，例如类风湿 关节炎，骨关节炎，肝炎，子宫内膜异位症，支气管哮喘，纤维化，糖尿病，动脉硬化，多发性硬化，肉芽肿，炎性肠病（溃疡性结肠炎和克罗恩病），自身免疫性疾病等。
-
公开(公告)号：US20090111126A1
公开(公告)日：2009-04-30
申请号：US11933819
申请日：2007-11-01
CPC分类号： C07K16/244 , C07K2317/23 , C07K2317/24 , C07K2317/622 , C07K2317/76
摘要： Disclosed are mammalian cell surface display vectors for isolating and/or characterizing immunoglobulins and various uses thereof.
摘要翻译： 公开了用于分离和/或表征免疫球蛋白的哺乳动物细胞表面展示载体及其各种用途。
-
公开(公告)号：US07365168B2
公开(公告)日：2008-04-29
申请号：US11102621
申请日：2005-04-08
申请人： Paul Hinton , Naoya Tsurushita , J. Yun Tso , Maximiliano Vasquez
发明人： Paul Hinton , Naoya Tsurushita , J. Yun Tso , Maximiliano Vasquez
CPC分类号： C07K16/00 , C07K16/082 , C07K16/249 , C07K16/2809 , C07K16/2833 , C07K16/2866 , C07K2317/21 , C07K2317/52 , C07K2317/732
摘要： The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
-
7.发明授权Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis 有权通过诱变改变抗体的FcRn结合亲和力或血清半衰期公开(公告)号：US07361740B2
公开(公告)日：2008-04-22
申请号：US10822300
申请日：2004-04-09
CPC分类号： C07K16/249 , C07K16/00 , C07K16/082 , C07K16/2809 , C07K16/2833 , C07K16/2866 , C07K2317/21 , C07K2317/52 , C07K2317/732
摘要： The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
摘要翻译： 本发明提供IgG类型的修饰抗体，其中来自选自氨基酸残基250,314和428的重链恒定区的至少一个氨基酸被另一个不同于 其存在于未修饰的抗体中，从而与未修饰的抗体相比改变对FcRn的结合亲和力和/或血清半衰期。
-
公开(公告)号：US20080063646A1
公开(公告)日：2008-03-13
申请号：US10581468
申请日：2004-11-10
IPC分类号： A61K39/395 , A61P29/00 , C07K16/00 , C07K16/24
CPC分类号： C07K16/24 , C07K2317/24 , C07K2317/76 , Y02E60/324
摘要： The present invention is directed to high affinity anti-human IP-10 antibodies or antigen-binding fragments of these antibodies, including chimeric, humanized or fully human antibodies. The present invention is also directed to a method of reducing the severity of at least one symptom of an inflammatory bowel disease in a subject in need thereof comprising administering to said subject an effective amount of an antagonist of IP-10, including the antibodies or antibody fragments of the present invention.
摘要翻译： 本发明涉及高亲和力抗人IP-10抗体或这些抗体的抗原结合片段，包括嵌合，人源化或完全人抗体。 本发明还涉及降低有需要的受试者中至少一种炎症性肠病症状的严重性的方法，其包括对所述受试者施用有效量的IP-10拮抗剂，包括抗体或抗体 本发明的片段。
-
9.发明申请Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis 有权通过诱变改变抗体的FcRn结合亲和力或血清半衰期公开(公告)号：US20050276799A1
公开(公告)日：2005-12-15
申请号：US11102621
申请日：2005-04-08
申请人： Paul Hinton , Naoya Tsurushita , J. Tso , Maximiliano Vasquez
发明人： Paul Hinton , Naoya Tsurushita , J. Tso , Maximiliano Vasquez
CPC分类号： C07K16/00 , C07K16/082 , C07K16/249 , C07K16/2809 , C07K16/2833 , C07K16/2866 , C07K2317/21 , C07K2317/52 , C07K2317/732
摘要： The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
摘要翻译： 本发明提供IgG类型的修饰抗体，其中来自选自氨基酸残基250,314和428的重链恒定区的至少一个氨基酸被另一个不同于 其存在于未修饰的抗体中，从而与未修饰的抗体相比改变对FcRn的结合亲和力和/或血清半衰期。
-
公开(公告)号：US06329511B1
公开(公告)日：2001-12-11
申请号：US09450520
申请日：1999-11-29
IPC分类号： C07K1600
CPC分类号： C07K16/249 , A61K2039/505 , C07K2317/24
摘要： The invention provides humanized immunoglobulins that bind to and neutralize &ggr;-interferon. The antibodies are useful for treatment of diseases of the immune system, particularly autoimmune diseases.
摘要翻译： 本发明提供结合并中和γ-干扰素的人源化免疫球蛋白。 抗体可用于治疗免疫系统疾病，特别是自身免疫性疾病。
-
-
-
-
-
-
-
-
-
搜索结果
61 条记录 (耗时 0.043 秒)
